- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lung Cancer | Clinical
MEDI5752 Plus Chemotherapy Produces Long DOR, But High Dose Comes With High Toxicity
September 11, 2022
Chemotherapy added to 1500 mg of MEDI5752, a PD-1/CTLA-4 bispecific monoclonal antibody, led to a doubling in duration of response compared with pembrolizumab and chemotherapy in patients with treatment-naïve nonsquamous non–small cell lung cancer.
Canakinumab Fails to Improve DFS in Resected NSCLC
September 11, 2022
Edward E. Garon, MS, MS, discusses results from the phase 3 CANOPY-A study of adjuvant canakinumab for the treatment of patients with completely resected non-small cell lung cancer.
Addition of Tremelimumab to Durvalumab/Chemo Continues to Improve OS in Metastatic NSCLC
September 11, 2022
Adding a limited course of tremelimumab to durvalumab plus chemotherapy induced long-term OS in patients with metastatic NSCLC, even when stratified by histology and mutation status.
Study Finds Air Pollutant Particulate May Impact EGFR-Positive Non-Small Cell Lung Cancer
September 10, 2022
A study of air pollutant particulate matter shows that it may be a mechanistic driver for lung cancer, showing a need to curb its source.
Nivolumab With or Without Relatlimab Displays Feasibility in Resectable NSCLC
September 09, 2022
The phase 2 NEOpredict trial of nivolumab with or without relatilmab met its primary end point of feasibility of treatment in patients with resectable non–small cell lung cancer.
Role of Tumor-Infiltrating Lymphocytes in Solid Tumors: Advancements in Therapeutic Strategy
September 08, 2022
In the first interview of this series, Allison Betof Warner, MD, PhD, reviews the mechanistic rationale of tumor-infiltrating lymphocytes and considers their potential use in the management of solid tumors.
Amivantamab Shows Strong Efficacy in NSCLC With EGFR Exon 20 Insertion
September 07, 2022
Erminia Massarelli, MD, PhD, MS, discusses the efficacy outcomes of the CHRYSALIS trial of amivantamab in patients with non–small cell lung cancer and an EGFR exon 20 insertion.
Amivantamab/Lazertinib/Chemotherapy Reveals Significant ORR Rates in NSCLC
September 07, 2022
In an interview with Targeted Oncology, Melina Elpi Marmarelis, MD, further discussed the findings revealed from the LACP cohort of the CHRYSALIS-2 study in non–small cell lung cancer.
Approaching Treatment for a Patient With NSCLC and an EGFR Mutation
September 06, 2022
During a live virtual event, Benjamin P. Levy, MD, discussed the case of a patient with non–small cell lung cancer and an EGFR exon 19 deletion. This is the second of two articles based on this event.
SELECT Study of Vopratelimab With/Without Pimivalimab Misses Primary End Point in NSCLC
August 31, 2022
Top-line data from the SELECT trial of vopratelimab plus pimivalimab vs pimivalimab alone missed its primary end point of mean tumor change but showed encouraging trends for secondary end points.